Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for VRX
8.60
+0.09 (1.06%)
After Hours: 8.64 +0.04 (0.47%)
Apr 24, 7:55PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 8.31 - 8.78
52 week 8.31 - 38.50
Open 8.56
Vol / Avg. 0.00/19.57M
Mkt cap 2.80B
P/E     -
Div/yield     -
EPS -6.92
Shares 341.19M
Beta -0.17
Inst. own 58%
May 9, 2017
Q1 2017 Valeant Pharmaceuticals International Inc Earnings Release - 9:30AM EDT - Add to calendar
May 9, 2017
Q1 2017 Valeant Pharmaceuticals International Inc Earnings Call - 8:00AM EDT - Add to calendar
May 2, 2017
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
Mar 15, 2017
Valeant Pharmaceuticals International Inc at Barclays Global Healthcare Conference
Mar 2, 2017
Valeant Pharmaceuticals International Inc at Deutsche Bank Pharma One-on-One Day
Feb 28, 2017
Q4 2016 Valeant Pharmaceuticals International Inc Earnings Release
Feb 28, 2017
Q4 2016 Valeant Pharmaceuticals International Inc Earnings Call
Feb 23, 2017
Valeant Pharmaceuticals International Inc at RBC Capital Markets Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -21.31% -24.89%
Operating margin 6.26% -5.85%
EBITD margin - 41.49%
Return on average assets -4.60% -5.21%
Return on average equity -56.40% -53.16%
Employees 21,500 -
CDP Score - D

Address

Laval, 2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Paul S. Herendeen Chief Financial Officer, Executive Vice President - Finance
Age: 60
Bio & Compensation  - Reuters
Pavel Mirovsky President, General Manager, Europe
Age: 65
Bio & Compensation  - Reuters
Christina Ackermann Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Thomas Appio Executive Vice President, President - Asia Pacific
Bio & Compensation  - Reuters
Louis W. Yu Ph.D. Chief Quality Officer, Global Quality
Age: 65
Bio & Compensation  - Reuters
Thomas W. Ross Sr. Lead Independent Director
Age: 65
Bio & Compensation  - Reuters
William A. Ackman Independent Director
Age: 50
Bio & Compensation  - Reuters
Richard U. DeSchutter Independent Director
Bio & Compensation  - Reuters
Fredric N. Eshelman Independent Director
Age: 67
Bio & Compensation  - Reuters